WHAT IS CLAIMED IS:

1. Use of a multi-chain chimeric polypeptide in the manufacture of a medicament for reducing inflammation in the liver of a subject, wherein the multi-chain chimeric polypeptide comprises:

(a) a first chimeric polypeptide comprising:

(i) a first target-binding domain;

(ii) soluble tissue factor domain; and

(iii) a first domain of a pair of affinity domains;

(b) a second chimeric polypeptide comprising:

(i) a second domain of a pair of affinity domains; and

(ii) a second target-binding domain,

wherein:

the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains, wherein the pair of affinity domains comprises a soluble IL-15 and a sushi domain from an alpha chain of human IL-15 receptor (IL-15Rα); and wherein

the first target-binding domain binds specifically to a ligand of TGF-β receptor II (TGF-βRII) and the second target-binding domain binds specifically to a ligand of TGF-βRII.

2. Use of a multi-chain chimeric polypeptide in the manufacture of a medicament for decreasing chemical induced steatosis in a liver of a subject, wherein the multi-chain chimeric polypeptide comprises:

(a) a first chimeric polypeptide comprising:

(i) a first target-binding domain;

(ii) soluble tissue factor domain; and

(iii) a first domain of a pair of affinity domains;

(b) a second chimeric polypeptide comprising:

(i) a second domain of a pair of affinity domains; and

(ii) a second target-binding domain,

wherein:

the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains, wherein the pair of affinity domains comprises a soluble IL-15 and a sushi domain from an alpha chain of human IL-15 receptor (IL-15Rα); and wherein

the first target-binding domain binds specifically to a ligand of TGF-β receptor II (TGF-βRII) and the second target-binding domain binds specifically to a ligand of TGF-βRII.

3. The use of claim 2, wherein the first target-binding domain and the soluble tissue factor domain directly abut each other in the first chimeric polypeptide.

4. The use of claim 2, wherein the first chimeric polypeptide further comprises a linker sequence between the first target-binding domain and the soluble tissue factor domain in the first chimeric polypeptide.

5. The use of claim 2, wherein the soluble tissue factor domain and the first domain of the pair of affinity domains directly abut each other in the first chimeric polypeptide.

6. The use of claim 2, wherein the first chimeric polypeptide further comprises a linker sequence between the soluble tissue factor domain and the first domain of the pair of affinity domains in the first chimeric polypeptide.

7. The use of claim 2, wherein the second domain of the pair of affinity domains and the second target-binding domain directly abut each other in the second chimeric polypeptide.

8. The use of claim 2, wherein second chimeric polypeptide further comprises a linker sequence between the second domain of the pair of affinity domains and the second target-binding domain in the second chimeric polypeptide.

9. The use of claim 2, wherein the soluble tissue factor domain is a soluble human tissue factor domain.

10. The use of claim 9, wherein the soluble human tissue factor domain comprises a sequence that is at least 80% identical to SEQ ID NO: 1.

11. The use of claim 2, wherein the first target-binding domain comprises a soluble TGF-βRII.

12. The use of claim 11, wherein the first target-binding domain comprises a first sequence that is at least 80% identical to SEQ ID NO: 2 and a second sequence that is at least 80% identical to SEQ ID NO: 2, wherein the first and second sequence are separated by a linker.

13. The use of claim 12, wherein the linker comprises a sequence of SEQ ID NO: 3.

14. The use of claim 2, wherein the second target-binding domain comprises a soluble TGF-βRII.

15. The use of claim 14, wherein the second target-binding domain comprises a first sequence that is at least 80% identical to SEQ ID NO: 2 and a second sequence that is at least 80% identical to SEQ ID NO: 2, wherein the first and second sequence are separated by a linker.

16. The use of claim 15, wherein the linker comprises a sequence of SEQ ID NO: 3.

17. The use of claim 2, wherein:

the first target-binding domain comprises a sequence that is at least 80% identical to SEQ ID NO: 4;

the soluble tissue factor domain comprises a sequence that is at least 80% identical to SEQ ID NO: 1;

the first domain of the pair of affinity domains comprises a sequence that is at least 80% identical to SEQ ID NO: 18;

the second target-binding domain comprises a sequence that is at least 80% identical to SEQ ID NO: 4; and

the second domain of the pair of affinity domains comprises a sequence that is at least 80% identical to SEQ ID NO: 16.

18. The use of claim 2, wherein:

the first chimeric polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 6; and

the second chimeric polypeptide comprises a sequence that is at least 80% identical to SEQ ID NO: 5.

19. The use of claim 2, wherein:

the first target-binding domain comprises a sequence that is at least 90% identical to SEQ ID NO: 4;

the soluble tissue factor domain comprises a sequence that is at least 90% identical to SEQ ID NO: 1;

the first domain of the pair of affinity domains comprises a sequence that is at least 90% identical to SEQ ID NO: 18;

the second target-binding domain comprises a sequence that is at least 90% identical to SEQ ID NO: 4; and

the second domain of the pair of affinity domains comprises a sequence that is at least 90% identical to SEQ ID NO: 16.

20. The use of claim 2, wherein:

the first target-binding domain comprises a sequence that is at least 95% identical to SEQ ID NO: 4;

the soluble tissue factor domain comprises a sequence that is at least 95% identical to SEQ ID NO: 1;

the first domain of the pair of affinity domains comprises a sequence that is at least 95% identical to SEQ ID NO: 18;

the second target-binding domain comprises a sequence that is at least 95% identical to SEQ ID NO: 4; and

the second domain of the pair of affinity domains comprises a sequence that is at least 95% identical to SEQ ID NO: 16.

21. The use of claim 2, wherein:

the first target-binding domain comprises SEQ ID NO: 4;

the soluble tissue factor domain comprises SEQ ID NO: 1;

the first domain of the pair of affinity domains comprises SEQ ID NO: 18;

the second target-binding domain comprises SEQ ID NO: 4; and

the second domain of the pair of affinity domains comprises SEQ ID NO: 16.

22. The use of claim 2, wherein:

the first chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO: 6; and

the second chimeric polypeptide comprises a sequence that is at least 90% identical to SEQ ID NO: 5.

23. The use of claim 2, wherein:

the first chimeric polypeptide comprises a sequence that is at least 96% identical to SEQ ID NO: 6; and

the second chimeric polypeptide comprises a sequence that is at least 96% identical to SEQ ID NO: 5.

24. The use of claim 2, wherein:
the first chimeric polypeptide comprises SEQ ID NO: 6; and
the second chimeric polypeptide comprises SEQ ID NO: 5.